InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of proprietary small-molecule d
Biotechnology, Pharmaceuticals
2025-11-18 7:30 AM EST | InMed Pharmaceuticals
TempraMed Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company") is pleased to announce that its common shares are now listed and trading on the Frankfurt Stock Exchange under the trading symbol "9DY." The Company is also pleased to announce it has retained bullVestor Medien GmbH ("bullVestor") to provide certain marketing services for a period of 3 months, commencing on November 18, 2025
Technology, Biotechnology, Pharmaceuticals, Health
2025-11-18 7:00 AM EST | TempraMed Technologies Ltd
Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress
King of Prussia, Pennsylvania--(Newsfile Corp. - November 17, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a podium presentation highlighting INTASYL® siRNA Drug Technology will be held at the Advanced Therapies USA 2025 Congress in Philadelphia, PA at the Pennsylvania Convention
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-17 8:45 AM EST | Phio Pharmaceuticals Corp.
Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
Ontario and Chicago, Illinois--(Newsfile Corp. - November 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into a new senior secured credit agreement with National Bank of Canada as administrative agent. The credit agreement provides for a US$21.0 million term loan facility and a US$5.0 million revolving loan facility. The term loan facility benefits from an additional US$10.0 million delayed draw feature, intended to finance future licensing and acquisitio
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-17 8:30 AM EST | Medexus Pharmaceuticals Inc.
Telescope Innovations to Deliver First Self-Driving Lab for Korea's Largest Biopharma Manufacturers Association
HIGHLIGHTS This installation for Korea's largest biopharma association represents the first Self-Driving Lab ("SDL") for drug development to be deployed in Korea Partnership supports Korea's transition toward automated and digital R&D SDL automates continuous experimental optimization using robotics, analytics, and AI SDLs show expanding commercial relevance across pharma, minerals, energy, agriculture, and chemical
Technology, Chemical, Pharmaceuticals, Psychedelics
2025-11-17 8:00 AM EST | Telescope Innovations Corp.
PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program
Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the therapeutic potential of ketamine for neuropsychiatric disorders, today announced that it has entered into an Exclusive Evaluation and Option-to-License Agreement (the "Agreement") with Oakwood Laboratories, LLC ("Oakwood") for the development and commercialization of Oakwood's patente
Biotechnology, Pharmaceuticals
2025-11-17 8:00 AM EST | PharmaTher Holdings Ltd.
Theralase(R) Investor Conference Call Reminder
Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses reminds investors that it will host a conference call on Wednesday, November 19th at 11:00 am ET to provide an update on the Company's ongoing Phase II clinical stu
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-11-17 7:00 AM EST | Theralase Technologies Inc.
Herbal Dispatch Announces Record-Breaking Month of $4.1M in Sales for October 2025
Vancouver, British Columbia--(Newsfile Corp. - November 17, 2025) - Herbal Dispatch Inc. (CSE: HERB) (OTC Pink: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company") is pleased to announce a record-breaking month of sales for October 2025 and an updated forecast for the fourth quarter of 2025, reflecting continued positive momentum. In October 2025, the Company achieved gross sales of approximately $4.1 million, marking the highest monthly sales in its history and
Pharmaceuticals, Cannabis, Cannabis Dispensary
2025-11-17 7:00 AM EST | Herbal Dispatch Inc.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - November 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the second quarter of fiscal year 2026 ended September 30, 2025 ("Second Quarter"). Consolidated revenues for the three-month period ending September 30, 2025, were $36.3 million, an increase of $17.4 million or approximately 92% as compared to the comparable period
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-14 4:19 PM EST | Elite Pharmaceuticals, Inc.
Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Clinical Trial has Advanced to Fifth and Final Cohort at Maximum Dose of INSTASYL PH-762 in Skin Cancer Trial Positive Pathology Results at Maximum Dose: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second Patient, Greater than 50% (Partial Response) in Third Patient Safety Monitoring Committee Issues Favorable Review of Safety Data at Maximum Dose of INTASYL PH-762 Warrant Inducement Fi
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-13 4:15 PM EST | Phio Pharmaceuticals Corp.
BioHarvest Sciences Reports Third Quarter 2025 Financial Results
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 13, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a
Biotechnology, Pharmaceuticals, Health
2025-11-13 4:05 PM EST | BioHarvest Sciences Inc.
Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway
Calgary, Alberta--(Newsfile Corp. - November 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced key highlights from its November 12, 2025 Grand Rounds presentation (to the University of Florida (UF, Gainesville) vascular team. The session, titled "Angiogenic Cell Precursors (ACP-01): Regenerating Microcirculation in CLI, Cardiomyopathy and Angina," was delivered by Fraser Henderson Sr., MD (neurosurgeon) with opening remarks and poli
Biotechnology, Pharmaceuticals, Health
2025-11-13 10:57 AM EST | Hemostemix Inc.
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Ontario and Chicago, Illinois--(Newsfile Corp. - November 12, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's second fiscal quarter ended September 30, 2025 (the company's fiscal Q2 2026). All dollar amounts in this press release are in United States dollars unless specified otherwise. Key business update Medexus is currently focused on delivering strong p
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-12 6:06 PM EST | Medexus Pharmaceuticals Inc.
BioHarvest Sciences to Attend the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to attend the Craig-Hallum 16th Annual Alpha Select Conference taking place on Tuesday, November 18th, 2025 in New York, NY.
Biotechnology, Pharmaceuticals, Health
2025-11-12 8:42 AM EST | BioHarvest Sciences Inc.
Elite Pharmaceuticals Receives FDA Approval for Generic Requip XL(R)
Northvale, New Jersey--(Newsfile Corp. - November 12, 2025) - Elite Pharmaceuticals, Inc. (OTCBB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets. Ropi
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-12 7:00 AM EST | Elite Pharmaceuticals, Inc.
BioHarvest Sciences Announces Closing of $19.9 Million Upsized Public Offering of Common Stock and Exercise of Underwriter's Option to Purchase Additional Shares
British Columbia and Rehovot, Israel--(Newsfile Corp. - November 10, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology platform, announces the closing of its previously announced underwritten public offering of 2,846,854 shares of common stock, no par value, and at a public offering price of $7.00 per share, which includes 361,854 shares issued upon the exercise by the
Biotechnology, Pharmaceuticals, Health
2025-11-10 4:18 PM EST | BioHarvest Sciences Inc.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025
Northvale, New Jersey--(Newsfile Corp. - November 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2026 fiscal year will be released on Friday, November 14, 2025. Elite's management will host a live conference call on Monday, November 17th, at 11:30 AM EST to discuss the company's financial and operating re
Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-10 7:00 AM EST | Elite Pharmaceuticals, Inc.
Theralase(R) Releases 3Q2025 Financial Statements
Toronto, Ontario--(Newsfile Corp. - November 10, 2025) - Theralase® Technologies Inc. (TSXV:TLT) (OTCQB:TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company's unaudited condensed consolidated interim 3Q2025 financial statements ("Financial Statements"). Theralase® will be host
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-11-10 7:00 AM EST | Theralase Technologies Inc.
Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it will present clinical data from its ongoing Phase 1b clinical trial at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in National Harbor, Ma
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-07 10:30 AM EST | Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program
King of Prussia, Pennsylvania--(Newsfile Corp. - November 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio announced today that its INTASYL compound PH-762 is the winner of the 2025 Immunomodulatory Solution of the Year award. This is the fifth annual BioTech Breakthrough Awards program conducted by
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-07 7:45 AM EST | Phio Pharmaceuticals Corp.